Toggle Offcanvas
...
 
Omalizumab Tenders

Omalizumab Tenders

View Omalizumab tenders, RFPs and contracts. Bid on readily available Omalizumab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Omalizumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Omalizumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Omalizumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Omalizumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

18 Live Notices for Omalizumab Tenders

Showing 1 to 18

Medications Outside The List Of Drugs
country Serbia
posting date10 Feb 2025
deadline11 Mar 2025
Omalizumab Drug Supply Agreement
country Chile
posting date07 Feb 2025
deadline17 Feb 2025
Subject: Electronic Auction - Acquisition Of Medicines.
country Brazil
posting date31 Jan 2025
deadline14 Feb 2025
* Price Record * Price Record For The Acquisition Of Capecitabine 500Mg Coated Tablet, Omalizumab 150Mg Fam And Osimertinib 80Mg Tablet
country Brazil
posting date30 Jan 2025
deadline18 Feb 2025
Subject: Electronic Auction - Acquisition Of Medicines, Aiming At Serving Patients Registered At Sespa Dispensing Units, In Order To Establish Full Supply Of Stock, Counting From The Signing Of The Contract.
country Brazil
posting date30 Jan 2025
deadline13 Feb 2025
Judicial Acquisition Of Medicines: Omalizumab 150Mg
country Brazil
posting date28 Jan 2025
deadline12 Feb 2025
Conclusion Of A Non-Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For Medicinal Products Containing The Active Ingredient Omalizumab (Atc Code: R03Dx05).
country Germany
posting date08 Oct 2024
deadline27 Sep 2026
Abschluss Eines Nicht Exklusiven Rabattvertrages Nach § 130A Abs. 8 Sgb V Zu Arzneimitteln Mit Dem Wirkstoff Omalizumab (Atc-Code: R03Dx05).
country Germany
posting date07 Oct 2024
deadline27 Sep 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Para. 8 Sgb V For The Active Ingredient Omalizumab
country Germany
posting date30 Aug 2024
deadline10 Aug 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab, Atc R03Dx05 (Obo) For The Period 01.08.2024 - 31.07.2025 (Plus Extension Option 1X12 Months)
country Germany
posting date21 Jun 2024
deadline05 Jun 2026
Open House Biologics Discount Agreements 2024-03 - Omalizumab
country Germany
posting date14 May 2024
deadline30 Jun 2026
Open House Biologics Discount Agreements 2024-03 - Omalizumab
country Germany
posting date13 May 2024
deadline30 Jun 2026
Conclusion Of Non-Exclusive Discount Agreements In Accordance With §§ 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Omalizumab (R03Dx05) As Part Of A So-Called Open House Model.
country Germany
posting date26 Jun 2023
deadline31 May 2025
Conclusion of non-exclusive discount agreements in accordance with §§ 130a Paragraph 8/130c Paragraph 1 SGB V for drugs with the active ingredient omalizumab (R03DX05) as part of a so-called open house model.
country Germany
posting date22 Jun 2023
deadline31 May 2025
Conclusion Of Non-Exclusive Discount Agreements In Accordance With §§ 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Omalizumab (R03Dx05) As Part Of A So-Called Open House Model.
country Germany
posting date22 Jun 2023
deadline31 May 2025
(2025-26 Ami Code- 17.13) Omalizumab Inj 150Mg Per Vial/Pfs
country India
posting date10 Feb 2025
deadline20 Feb 2025
Omalizumab 150 Mg Injection
country India
posting date08 Feb 2025
deadline11 Feb 2025
Omalizumab 150 Mg Injection
country India
posting date08 Feb 2025
deadline11 Feb 2025

Share Share this page